Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ammoxetine Hydrochloride PK Study Under Fasting and Fed Conditions
NCT07508462Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ammoxetine (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Pharmacokinetic parameters at 48 hours. Started May 2024; status: completed.
02
Drugs
ammoxetine
Beyond the preview
Go deeper on NCT07508462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508462.